Sumary of Combatting Crimean-Congo haemorrhagic fever with COVID technology:
- © iStock/nopparit A scientific research consortium called Prometheus is employing the same framework used to develop COVID-19 vaccines to tackle Crimean-Congo haemorrhagic fever.
- Crimean-Congo haemorrhagic fever (CCHF) is a devastating tick-borne virus that causes death in around 40% of cases, with the World Health Organization (WHO) recently placing it as one of its top priorities for research and development.
- Crimean-Congo haemorrhagic fever is commonly transmitted by ticks, with disease experts warning that the threat of the virus could grow due to the tick responsible for its dissemination becoming more prominent because of climate change and other factors.
- Jason McLellan, a professor of molecular biosciences at the University of Texas at Austin and a co-corresponding author on the study, said: “Crimean-Congo haemorrhagic fever is a terrible disease and is endemic in Africa, Asia and Europe, without any approved vaccines or antibody therapies to date.
- ” Exploring antibodies The Prometheus team identified two antibodies from recovered Crimean-Congo haemorrhagic fever patients that potentially neutralise the virus.
- Next, they combined the virus-binding regions of the two antibodies to create a ‘bispecific antibody’ that cured infections in sick mice models and protected uninfected mice from Crimean-Congo haemorrhagic fever.
- ” Tackling Crimean-Congo haemorrhagic fever The novel bispecific antibody could help patients recover who are already infected with Crimean-Congo haemorrhagic fever, prevent mortality, and help develop a future vaccine against the virus.
- Crimean-Congo haemorrhagic fever relies on a shape-shifting molecule on its surface – the Gc protein – to fuse with host cells.